CR20180348A - Nuevos anticuerpos anti-claudina y sus métodos de uso - Google Patents

Nuevos anticuerpos anti-claudina y sus métodos de uso

Info

Publication number
CR20180348A
CR20180348A CR20180348A CR20180348A CR20180348A CR 20180348 A CR20180348 A CR 20180348A CR 20180348 A CR20180348 A CR 20180348A CR 20180348 A CR20180348 A CR 20180348A CR 20180348 A CR20180348 A CR 20180348A
Authority
CR
Costa Rica
Prior art keywords
methods
antibodies
claudine
new anti
cldn
Prior art date
Application number
CR20180348A
Other languages
English (en)
Inventor
Samuel A ; Williams
Vikram Natwarsinhji; Sisodiya
Sarah; Fong
Robert A ; Stull
Original Assignee
Abbvie Stemcentrx Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Stemcentrx Llc filed Critical Abbvie Stemcentrx Llc
Publication of CR20180348A publication Critical patent/CR20180348A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

En la presente se proveen nuevos anticuerpos y conjugados de anticuerpo y fármaco anti-CLDN (ADC), incluyendo a derivados de los mismos, y métodos para usar los mismos para tratar trastornos proliferativos
CR20180348A 2015-12-04 2016-12-02 Nuevos anticuerpos anti-claudina y sus métodos de uso CR20180348A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562263542P 2015-12-04 2015-12-04
US201662427027P 2016-11-28 2016-11-28
PCT/US2016/064617 WO2017096163A1 (en) 2015-12-04 2016-12-02 Novel anti-claudin antibodies and methods of use

Publications (1)

Publication Number Publication Date
CR20180348A true CR20180348A (es) 2018-08-23

Family

ID=58797837

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20180348A CR20180348A (es) 2015-12-04 2016-12-02 Nuevos anticuerpos anti-claudina y sus métodos de uso

Country Status (23)

Country Link
US (1) US20190083645A1 (es)
EP (1) EP3383917A4 (es)
JP (1) JP2019500335A (es)
KR (1) KR20180088445A (es)
CN (1) CN108473588A (es)
AU (1) AU2016364853A1 (es)
BR (1) BR112018011319A2 (es)
CA (1) CA3006738A1 (es)
CL (2) CL2018001481A1 (es)
CO (1) CO2018005752A2 (es)
CR (1) CR20180348A (es)
DO (1) DOP2018000138A (es)
EC (1) ECSP18049762A (es)
HK (1) HK1254743A1 (es)
IL (1) IL259681A (es)
MA (1) MA43385A (es)
MX (1) MX2018006782A (es)
PE (1) PE20181302A1 (es)
PH (1) PH12018501153A1 (es)
RU (1) RU2018124319A (es)
SG (1) SG11201804673WA (es)
TW (1) TW201726175A (es)
WO (1) WO2017096163A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA40921A (fr) * 2014-11-05 2017-09-12 Abbvie Stemcentrx Llc Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation
AU2017294276B2 (en) 2016-07-08 2024-08-01 Crage Medical Co., Limited Antibody for anti-claudin 18A2 and use thereof
DK3668874T3 (da) * 2017-08-18 2022-02-14 Medimmune Ltd Pyrrolobenzodiazepin-konjugater
CR20200145A (es) * 2017-09-02 2020-08-03 Abbvie Inc Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos
US20200297863A1 (en) * 2017-09-02 2020-09-24 Abbvie Inc. Anti-egfr antibody drug conjugates (adc) and uses thereof
IL301637B2 (en) 2017-09-29 2024-10-01 Daiichi Sankyo Co Ltd Antibody-pyrrolobenzodiazepine derivative conjugate
US20210283141A1 (en) * 2018-05-25 2021-09-16 Medimmune Limited Pyrrolobenzodiazepine conjugates
EP3924389A4 (en) 2019-02-15 2023-06-14 Integral Molecular, Inc. CLAUDIN-6 ANTIBODIES AND THEIR USES
AU2020241896A1 (en) * 2019-03-20 2021-09-23 The Regents Of The University Of California Claudin-6 antibodies and drug conjugates
EP3950061A4 (en) 2019-03-25 2022-11-16 Daiichi Sankyo Company, Limited ANTIBODY PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE
BR112022008653A2 (pt) 2019-11-05 2022-07-19 Lanova Medicines Ltd Conjugado anticorpo-fármaco, método para tratar câncer, e, uso do conjugado anticorpo-fármaco
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
KR102451185B1 (ko) * 2021-08-05 2022-10-07 환인제약 주식회사 도네페질 함유 지속방출형 미립구
CN114878728A (zh) * 2022-05-06 2022-08-09 浙江大学 一种新型的抗体肽图检测还原方法
EP4626933A1 (en) 2022-11-30 2025-10-08 Integral Molecular, Inc. Antibodies directed to claudin 6, including bispecific formats thereof
US12403202B2 (en) 2023-05-25 2025-09-02 The Regents Of The University Of California Dosage of claudin-6 conjugates for cancer treatment
WO2025209525A1 (zh) * 2024-04-03 2025-10-09 江苏恒瑞医药股份有限公司 抗cldn6抗体、其抗体-药物偶联物及其医药用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003300705A1 (en) * 2003-12-31 2005-07-21 Council Of Scientific And Industrial Research C2-fluoro pyrrolo(2,1-c)(1,4)benzodiazepine dimers
US7189710B2 (en) * 2004-03-30 2007-03-13 Council Of Scientific And Industrial Research C2-fluoro pyrrolo [2,1−c][1,4]benzodiazepine dimers
MX391454B (es) * 2010-04-15 2025-03-05 Seagen Inc Compuesto de engarce-fármaco para conjugación a una unidad de ligando.
CN104837502B (zh) * 2012-10-12 2018-08-10 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其结合物
WO2014075697A1 (en) * 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
PE20160870A1 (es) * 2013-11-06 2016-09-09 Abbvie Stemcentrx Llc Anticuerpos anti-claudina novedosos y metodos de uso

Also Published As

Publication number Publication date
EP3383917A1 (en) 2018-10-10
BR112018011319A2 (pt) 2018-12-04
RU2018124319A (ru) 2020-01-09
MX2018006782A (es) 2018-11-09
AU2016364853A1 (en) 2018-06-21
PE20181302A1 (es) 2018-08-09
HK1254743A1 (zh) 2019-07-26
JP2019500335A (ja) 2019-01-10
KR20180088445A (ko) 2018-08-03
EP3383917A4 (en) 2019-08-21
DOP2018000138A (es) 2018-12-31
CL2019000189A1 (es) 2019-06-07
CL2018001481A1 (es) 2018-08-24
MA43385A (fr) 2018-10-10
CA3006738A1 (en) 2017-06-08
SG11201804673WA (en) 2018-06-28
CO2018005752A2 (es) 2018-06-12
ECSP18049762A (es) 2018-07-31
US20190083645A1 (en) 2019-03-21
CN108473588A (zh) 2018-08-31
IL259681A (en) 2018-07-31
PH12018501153A1 (en) 2019-01-28
WO2017096163A1 (en) 2017-06-08
TW201726175A (zh) 2017-08-01

Similar Documents

Publication Publication Date Title
DOP2018000138A (es) Nuevos anticuerpos anti-claudina y sus métodos de uso
PE20160870A1 (es) Anticuerpos anti-claudina novedosos y metodos de uso
CL2019000334A1 (es) Nuevos conjugados de anticuerpo y usos de los mismos (divisional solicitud 201502357)
DOP2017000052A (es) Nuevos anticuerpos anti-mfi2 y metodos de uso
CL2018000595A1 (es) Anticuerpos anti-pd1 y métodos de uso
CL2017003240A1 (es) Anticuerpos anti-rnf43 novedosos y métodos para su uso
ECSP17031725A (es) Receptores quiméricos de anitígeno anti-clon y métodos de uso
CO2018001624A2 (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso
CO2018005433A2 (es) Conjugados de fármaco de anticuerpo her2 específicos de sitio
MX2016002574A (es) Nuevos moduladores del homologo 6 (sez6) y metodos de uso.
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
MX2017010667A (es) Anticuerpos anti-proteína que contiene domino de inmunologlubina relacionado con el receptor de poliovirus (pvrig) y metodos de unso.
PH12016501109A1 (en) Novel anti-dpep3 antibodies and methods of use
CL2016000468A1 (es) Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso.
CO2018013298A2 (es) Anticuerpos anti-gitr y sus usos.
ECSP20082970A (es) Conjugados de fármaco y anticuerpo anti-sez6 y métodos de uso
MX2018007818A (es) Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.
CO2017010692A2 (es) Construcciones de calicheamicina y sus métodos de uso
MX2018013484A (es) Nuevos anticuerpos anti-tnfrsf21 y modos de uso.
AR101757A1 (es) Anticuerpos anti-mfi2 y métodos de uso